PMID- 16271957
OWN - NLM
STAT- MEDLINE
DCOM- 20060123
LR  - 20171116
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 163
IP  - 1
DP  - 2005 Nov
TI  - CD79a expression in acute myeloid leukemia t(8;21) and the importance of 
      cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity.
PG  - 62-7
AB  - Acute leukemias that express antigens associated with more than one lineage have 
      been classified as acute lymphocytic leukemia with myeloid markers, acute myeloid 
      leukemia with lymphoid markers, or biphenotypic acute leukemia (BAL). Antibody to 
      cytoplasmic CD79a has been recently introduced to flow cytometry. CD79a functions 
      in and has a high degree of specificity for B-cell differentiation. It has only 
      recently begun to be reported in biphenotypic acute leukemias. Cases of acute 
      leukemia submitted to the flow cytometry laboratory were retrospectively reviewed 
      beginning from the time analysis for cytoplasmic CD79a was added to leukemia and 
      lymphoma panels. Among 89 cases of AML, 2 showed strong coexpression of CD79a. 
      Both cases were differentiated FAB AML-M2 and demonstrated the t(8;21) with 
      cytogenetics and the AML1/ETO rearrangement with fluorescence in situ 
      hybridization (FISH). These are recurring abnormalities in FAB AML-M2. The 
      immunophenotyping met proposed scoring criteria for a diagnosis of BAL. 
      Nevertheless, the cytogenetic and FISH findings indicate that CD79a, despite its 
      specificity for B-cell differentiation, represented the aberrant presence of a 
      B-cell antigen in leukemias of distinct myeloid linage. It is doubtful that, in 
      this setting, CD79a expression should be considered a manifestation of lineage 
      ambiguity.
FAU - Kozlov, Igor
AU  - Kozlov I
AD  - Department of Pathology, University of Mississippi Medical Center, Jackson, MS 
      39216-4505, USA.
FAU - Beason, Kevin
AU  - Beason K
FAU - Yu, Cheng
AU  - Yu C
FAU - Hughson, Michael
AU  - Hughson M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 0 (Antigens, CD)
RN  - 0 (CD79 Antigens)
RN  - 04079A1RDZ (Cytarabine)
SB  - IM
CIN - Cancer Genet Cytogenet. 2007 Apr 1;174(1):76-7. PMID: 17350472
MH  - Acute Disease
MH  - Adult
MH  - Antigens, CD/genetics/immunology
MH  - B-Lymphocytes/immunology
MH  - Blast Crisis
MH  - Bone Marrow Cells/pathology
MH  - CD79 Antigens/*genetics/immunology
MH  - *Chromosomes, Human, Pair 21
MH  - *Chromosomes, Human, Pair 8
MH  - Cytarabine/therapeutic use
MH  - Flow Cytometry
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myeloid/blood/*genetics/immunology/pathology
MH  - Male
MH  - T-Lymphocytes/immunology
MH  - *Translocation, Genetic
EDAT- 2005/11/08 09:00
MHDA- 2006/01/24 09:00
CRDT- 2005/11/08 09:00
PHST- 2005/03/29 00:00 [received]
PHST- 2005/06/01 00:00 [revised]
PHST- 2005/06/02 00:00 [accepted]
PHST- 2005/11/08 09:00 [pubmed]
PHST- 2006/01/24 09:00 [medline]
PHST- 2005/11/08 09:00 [entrez]
AID - S0165-4608(05)00300-6 [pii]
AID - 10.1016/j.cancergencyto.2005.06.002 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2005 Nov;163(1):62-7. doi: 
      10.1016/j.cancergencyto.2005.06.002.